MindMaze secures $105 million financing to accelerate its global commercial growth plans

MindMaze a global pioneer in the multibillion-dollar digital neurotherapeutics market, today announced it has secured a $105 million financing round to accelerate its global commercial growth plans, supercharge ongoing R&D and consolidate the clinical development pipeline of its industry-defining digital therapeutic solutions for a wide spectrum of neurological diseases.MindMaze was a Venture Kick winner and a Venture Leader in 2010 and one of the TOP 100 Swiss Startups from 2013 to 2017.

The financing was led by Concord Health Partners, AlbaCore Capital Group, and Hambro Perks. The $105 million financing will accelerate MindMaze's global commercial growth plans, supercharge ongoing R&D and consolidate the clinical development pipeline of its industry-defining digital therapeutic solutions for a wide spectrum of neurological diseases. “This funding allows us to ramp up commercial activity and expand our footprint in the U.S, as well as gain access to strategic partners as we continue to deploy solutions across the continuum of care globally,” said Tej Tadi, Founder, and CEO of MindMaze.

Furthermore, as a result of Concord’s investment, MindMaze will initiate a partnership with The American Hospital Association. The AHA is committed to the advancement of innovative healthcare solutions and serves as the national advocate for its provider member organizations, including nearly 90% of US hospitals, health systems, and other healthcare organizations as well as 300,000 executives from healthcare organizations in the field.